Tianjin Jikun Pharmaceutical Technology

Tianjin Jikun Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Tianjin, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on addressing significant unmet medical needs in metabolic diseases, autoimmune disorders, and oncology. Its lead clinical candidate, JK-2122, is a highly selective URAT1 inhibitor currently in Phase 2 development for the treatment of hyperuricemia and gout. Additionally, Jikun is advancing JK-1102, a TYK2 inhibitor for autoimmune conditions, and JK-06, an FXR agonist for metabolic liver diseases. By leveraging its proprietary drug discovery platform, the company aims to deliver high-quality, affordable medicines to patients globally.